Академический Документы
Профессиональный Документы
Культура Документы
JPMorgan Funds
Fund overview
ISIN
LU0432979374
Bloomberg
JPHLTUA LX
Higher risk/
potential reward
Performance
Reuters
LU0432979374.LUF
Fund assets
USD 3504.5m
Domicile Luxembourg
Entry/exit charges
NAV USD 252.72 Entry charge (max) 5.00%
Exit charge (max) 0.50%
Fund launch
TER (max) 1.80%
2 Oct 2009
(Total Expense Ratio)
Class launch
Annual management + expenses
2 Oct 2009
=TER
31 Aug 2011
31 Aug 2016
Share class
currency USD
Fund ratings
As at 31 August 2016
TM
2012
22.12
17.54
Dividend History
Amount
$0.01
$0.01
$1.51
$2.96
$2.96
Record Date
12 Sep 2013
16 Sep 2014
15 Sep 2015
31 Aug 2016
31 Aug 2016
Payment Date
30 Sep 2013
30 Sep 2014
30 Sep 2015
26 Sep 2016
26 Sep 2016
Annualised yield
0.00%
0.00%
0.52%
1.19%
1.19%
2013
61.04
36.27
2014
22.01
18.10
2015
2.14
6.60
YTD
9.59
1.41
RETURN (%)
1 month
4.00
4.15
3 months
0.50
1.00
1 year
12.59
1.04
3 years
9.91
11.90
ANNUALISED
5 years
10 years
18.40
9.48
15.33
8.50
PORTFOLIO ANALYSIS
PERFORMANCE DISCLOSURES
Past performance is not a guide to current and future performance. The
value of your investments and any income from them may fall as well as
rise and you may not get back the full amount you invested.
Source: J.P. Morgan Asset Management. Share class performance is shown
based on the NAV (net asset value) of the share class with income (gross)
reinvested including actual ongoing charges excluding any entry and exit fees.
Indices do not include fees or operating expenses and you cannot invest in
them.
Dividend income shown is gross of any applicable tax.
Measurement
Correlation
Alpha
Beta
Annualised volatility
Sharpe ratio
Tracking error
Information ratio
3 years
0.91
1.77
1.16
15.03
0.70
6.53
0.21
5 years
0.90
2.66
1.24
15.83
1.14
7.34
0.44
Holdings
TOP 10
Sector
As at 31 July 2016
Roche
GlaxoSmithKline
Gilead Sciences
Bristol
BristolMyers Squibb
Novo Nordisk
Allergan
Shire
UnitedHealth
Eli Lilly & Co
Humana
% of assets
Pharmaceutical
Pharmaceutical
Biotechnology
Pharmaceutical
Pharmaceutical
Pharmaceutical
Biotechnology
Healthcare Services
Pharmaceutical
Healthcare Services
6.5
5.7
4.4
4.3
3.9
3.8
3.8
3.5
3.1
3.1
Compared to benchmark
REGIONS (%)
North America
Europe & Middle East ex UK
United Kingdom
Japan
Pacific ex
exJapan
Cash
68.6
19.9
9.5
1.1
0.0
0.9
+1.1
+0.3
+3.4
4.2
1.5
+0.9
38.3
36.5
15.7
8.6
0.9
Compared to benchmark
11.1
+18.5
+1.3
9.6
+0.9
SECTORS (%)
Pharmaceutical
Biotechnology
Healthcare Services
Medtech
Cash
> 100 bn
10 bn <> 100 bn
1 bn <> 10 bn
< 1 bn
Key risks
The value of equity securities may go down as well
as up in response to the performance of individual
companies and general market conditions.
Emerging markets may be subject to increased
GENERAL DISCLOSURES
Before investing, obtain and review the current
prospectus, Key Investor Information
Document (KIID) and any applicable local
offering document. These documents, as well as
the annual and semiannual reports and the
articles of incorporation, are available free
from your financial adviser, your J.P. Morgan
Asset Management regional contact, the funds
issuer (see below) or at www.jpmam.lu.
This material should not be considered as advice or
an investment recommendation. Fund holdings
and performance are likely to have changed since
the report date. No provider of information
presented here, including index and ratings
information, is liable for damages or losses of any
type arising from use of their information.
Information from communications with you will be
recorded, monitored, collected, stored and processed
consistent with our EMEA Privacy Policy available at
www.jpmorgan.com/pages/privacy
INFORMATION SOURCES
Fund information, including performance
calculations and other data, is provided by J.P.
DEFINITIONS
Morgan Asset Management (the marketing name
for the asset management businesses of
Overall Morningstar Rating TM assessment of a
JPMorgan Chase & Co and its affiliates worldwide).
All data is as at the document date unless indicated
fund
funds past performance, based on both return and
otherwise.
risk and shows how similar investments compare
Morningstar Ratings : Morningstar. All Rights
with their competitors. Investment decisions
Reserved. For further information visit
should not be based on a high rating alone.
http://corporate.morningstar.com/bf/asp/home.aspx?Correlation measures the relationship between
xmlfile=5028.xml
the movement of the fund and its benchmark. A